Diligence memo · auto-generated · as of July 3, 2026
Rapid Therapeutic Science Laboratories, Inc.
Rapid Therapeutic Science Laboratories, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Rapid Therapeutic Science Laboratories, Inc. operates in Biotech / Pharma, based in DALLAS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Rapid Therapeutic Science Laboratories, Inc. has raised $2.1M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.3M on 2020-03-27.
Most recent recorded round closed around 2021-01-22.
Valuation (modeled)modeled
Provath models Rapid Therapeutic Science Laboratories, Inc. at approximately $15M (range $369K–$103M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.45× the median modeled value of Seed Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era. Issuer reports $0–$1M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 5.4 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 38% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 37% of those peers.
Closest niche peers: rMark Bio, Inc., Massive Bio, Inc., Light Bio, Inc., Agronomed Pharmaceuticals LLC, Cellix Biosciences, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.